Key result
cMyBP-C phosphorylation decreases myosin and actin binding while HCM-linked mutations increase it.
Why the study?
cMyBP-C phosphorylation is significantly altered in cardiomyopathies and heart failure, but how cMyBP-C interacts with myosin and actin required investigation.
Population
cMyBP-C N-terminal domains (C0-C2), myosin, and actin filaments
Comparison
5 HCM-linked variants or functional mutations vs wild-type across unphosphorylated and phosphorylated C0-C2
Design
In vitro high-throughput FRET-based binding assay study
Authors
Loading...
May inform HCM therapies targeting cMyBP-C; leaves open human validation and clinical translation.
Phosphorylation and HCM-linked mutations have opposite effects on the binding of cMyBP-C to myosin and actin, highlighting the critical role of cMyBP-C phosphorylation in normal cardiac function and the potential for targeted therapies.
Wong et al. (2023) studied Cardiomyopathies and heart failure. Phosphorylation and HCM-linked M-domain mutations in cMyBP-C vs. Unphosphorylated and wild-type cMyBP-C was evaluated on Binding to myosin and actin. Phosphorylation of cMyBP-C decreases binding to myosin and actin, whereas HCM-linked M-domain mutations generally increase binding, with the greatest effects seen in the phosphorylated state.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: